Post-earnings recap
Reported
Tue, Nov 12, 2024
EPS actual
$-0.60
EPS est.
$-0.10
EPS surprise
-471.43%
1-day move
-9.10%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Corvus Pharmaceuticals reported a significant loss per share of $0.60, which contributed to a 9.1% decline in its stock price. The lack of revenue data and guidance may raise concerns among investors about the company's financial health and future prospects. The market's reaction reflects uncertainty regarding the company's performance and direction.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.60 | N/A | -471.43% |
| Revenue | — | N/A | — |
No transcript is on record, and the analysis is based on numerical results only.